- Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development
- The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT
- It will focus on the psychedelics industry, showcasing the latest research and development within the sector
- Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline
In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development.
The virtual event, scheduled on Wednesday, July 7, 2021, from 11:50 a.m. to 12:50 p.m. EDT, will focus on the psychedelics industry, mainly showcasing the latest research and development within the sector (https://nnw.fm/YPB3G). The event is also intended to expand businesses currently looking for capital, mainly by directly delivering the industry’s most promising opportunities to funds and investors.
The July 7 event marks the second global psychedelics industry investment event that solely focuses on research and development. As has been the case with the previous events, this one is meant to showcase the latest clinical evidence for this promising sector. It will feature a concise half-day program, with provisions for interactions with industry leaders, global psychedelics investors and rising entrepreneurs (https://nnw.fm/4fgem).
Tryp Therapeutics is a pharmaceutical enterprise committed to developing bioscience solutions for conditions with unmet needs (https://nnw.fm/cbIm0). Its current flagship program involves developing a synthetic psychedelic drug candidate specifically designed to treat particular pain and eating disorder indications. Its trademarked Psilocybin-for-Neuropsychiatric Disorder (“PFN”) program is the basis for the company’s development of treatments for several diseases that lack effective treatment options (https://nnw.fm/vqr1D).
At this Psych Investor Summit, Tryp Therapeutics, through its Chairman and Chief Executive Officer, Mr. Greg McKee, will share the strides that it has made so far. More specifically, Mr. McKee will delve into more detail on Tryp’s drug development pipeline and what it is doing to push the envelope regarding the use of psychedelics to treat specific types of pain and diseases (https://nnw.fm/TPxai).
Mr. McKee will also contribute to a panel discussion on the future of research and development and the development activities for psychedelic drug compounds. Other speakers presenting at the conference include Rick Doblin, the Founder and Executive Director of MAPS; Christian Angermayer, the Founder of atai Life Sciences; and Dr. Ben Sessa, the Chief Medical Officer at Awkn Life Sciences.
For more information, visit the company’s website at www.TrypTherapeutics.com. Should you wish to attend the summit, you can register at www.Psych.Global/agenda/.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
